CRVS Corvus Pharmaceuticals Inc Earnings per share for the last twelve months

The potential of Corvus Pharmaceuticals (CRVS) is based on the implementation of targeted immunotherapies for lymphoma treatment. On GURU.Markets, the 12-month net income per share trend demonstrates the model's adaptability, where -0.70 represents the current metric. However, business sustainability depends on test results and competition, while the start of final Phase 3 trials is still being established.
Analytical breakdowns and data insights for company Corvus Corp (CRVS)

This indicator reflects the annual net income per share, allowing investors to filter out market noise and assess the actual return on equity. By analyzing the 12-month rolling earnings per share, an investor can see the impact of geopolitical barriers and logistics disruptions on drug development costs, which inevitably hinders the profit growth of Corvus Pharmaceuticals (CRVS) due to the complexity of international trials.